8-K: Kyverna Therapeutics: Positive Phase 2 Data for Miv-cel in gMG

Kyverna Therapeutics announced positive longer-term Phase 2 data for its miv-cel therapy in generalized myasthenia gravis, showing deep and durable responses.

Summary

• Kyverna Therapeutics presented updated longer-term follow-up data from the Phase 2 portion of its KYSA-6 trial for miv-cel (mivocabtagene autoleucel) in patients with generalized myasthenia gravis (gMG).
• The data, presented at the American Academy of Neurology (AAN) Annual Meeting, demonstrated deep and durable clinical responses sustained up to one year after a single dose of miv-cel.
• All seven treated patients showed rapid and sustained improvements in MG-ADL and QMG scores, with 57% achieving minimal symptom expression (MG-ADL score of 0 or 1) at last follow-up.
• The therapy was well-tolerated, with no high-grade cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) observed.
• Kyverna is advancing miv-cel in a Phase 2/3 registrational trial (KYSA-6) and will host a conference call on April 22, 2026, to discuss the results.

Sentiment

Score: 9

Explanation: StockSavvy.ai views this as a highly positive announcement due to the strong efficacy and safety data presented, reinforcing the potential of miv-cel as a best-in-class therapy.

Positives

• 100% of patients achieved rapid, robust, and sustained reductions in MG-ADL and QMG scores from baseline.
• Deep responses were sustained out to 52 weeks in patients with available follow-up.
• 57% of patients achieved minimal symptom expression (MSE) at last follow-up.
• 100% of patients were free of nonsteroidal immunosuppressants, high-dose steroids, and FcRn and complement inhibitors through Week 24.
• Robust CAR T-cell expansion led to deep B-cell depletion and evidence of immune reset.
• Reduced autoantibody levels with preservation of humoral immunity observed at week 12.
• Miv-cel demonstrated a well-tolerated safety profile, supporting potential for outpatient administration.
• No high-grade cytokine release syndrome (CRS) and no immune effector cell-associated neurotoxicity syndrome (ICANS) events were observed.

Negatives

• Two patients experienced transient grade 3/4 treatment-related AEs of neutropenia, which were expected and resolved.
• The trial is single-arm, open-label, which limits direct comparison without a control group in the Phase 2 portion.

Risks

• Actual results may differ materially from forward-looking statements due to uncertainties related to market conditions.
• Prior clinical trial results may not be predictive of future results.
• Regulatory agencies like the FDA may require additional trials or studies to support the Biologics License Application (BLA) submission.
• Intellectual property rights could pose a challenge.
• Other factors discussed in Kyverna's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q.

Future Outlook

Kyverna Therapeutics is advancing miv-cel in the Phase 3 portion of the KYSA-6 trial, which is currently enrolling patients. The company anticipates that the positive Phase 2 data will increase confidence in the Phase 3 trial and reinforce miv-cel's potential best-in-class profile for delivering durable, drug-free, disease-free remission with a single dose.

Management Comments

• "We are pleased to share updated data for miv-cel that continue to demonstrate the depth and durability of response across key outcome measures in patients with generalized myasthenia gravis, setting a new clinical standard."
• "Our data reinforces confidence in miv-cel's differentiated profile, strengthens our conviction in the ongoing Phase 3 trial, and more broadly solidifies our leadership in neuroimmunology CAR T."
• "The ability of miv-cel to achieve minimal symptom expression while eliminating the need for chronic immunotherapies following a single dose represents a meaningful clinical advancement with the potential to significantly improve daily function and quality of life for patients."
• "These profound and unprecedented results are driven by miv-cel's unique ability to target the disease at the source, deeply depleting B-cells to drive an immune reset and achieve durable drug-free, disease-free remission for patients with generalized myasthenia gravis."
• "The consistency of the results across all primary and secondary endpoints, further supported by biomarker data, is highly encouraging and underscores miv-cel's potential to change the treatment paradigm with a single dose."

Industry Context

StockSavvy.ai notes that Kyverna Therapeutics' positive results in generalized myasthenia gravis align with the broader trend in the biopharmaceutical industry towards developing targeted cell therapies for autoimmune diseases, aiming for durable remission and reduced reliance on chronic immunosuppression.

Stakeholder Impact

• Shareholders: Positive data may lead to increased confidence and potential stock price appreciation.
• Patients: Potential for a new, effective, and durable treatment option for generalized myasthenia gravis, possibly reducing the need for chronic immunosuppressants and improving quality of life.
• Healthcare Providers: Provides a new therapeutic option with a potentially favorable safety profile for managing gMG.
• Regulatory Bodies (e.g., FDA): Data supports the ongoing registrational trial and potential future BLA submission.

Next Steps

• Continue enrollment in the Phase 3 portion of the KYSA-6 trial.
• Host conference call on April 22, 2026, to review results.
• Present updated Phase 2 data from the KYSA-8 trial (stiff person syndrome) at AAN.

Key Dates

Recommendation

The presented longer-term Phase 2 data for miv-cel in gMG demonstrates significant efficacy with deep, durable responses and a favorable safety profile, reinforcing its potential as a best-in-class therapy. This strong clinical validation, coupled with the advancement into Phase 3 trials, suggests a high probability of regulatory approval and market success, warranting a strong buy recommendation.

Keywords

miv-cel, Kyverna Therapeutics, generalized myasthenia gravis, gMG, CAR T-cell therapy, autoimmune diseases, KYSA-6 trial, Phase 2 data